Beam Therapeutics (BEAM) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
10 Nov, 2026Editing platform
Base editing uses RNA-guided Cas9 targeting without double-stranded DNA breaks; attached deaminase enzymes enable A-to-G or C-to-T changes.
Four programs are in clinical development, spanning ex vivo sickle cell treatment and in vivo LNP-based editing for liver diseases.
Risto-cel for sickle cell disease
BEACON met all primary and secondary efficacy and safety endpoints; a BLA filing is targeted as early as year-end 2026.
Risto-cel showed the highest reported hemoglobin F, reduced hemoglobin S below 40%, normalized hemoglobin, and reduced blood viscosity.
Automated manufacturing supports reliable dosing; median mobilization was one, with the vast majority of trial participants requiring two or fewer mobilizations.
Dose is 3.5 million cells/kg; base editing requires fewer starting cells, while faster neutrophil engraftment may reduce infection risk and hospital stays.
In vivo programs
BEAM-302 for alpha-1 antitrypsin deficiency is in pivotal phase; FDA agreement supports accelerated approval, with pivotal completion expected in H1 2027.
At 60 mg, all patients reached the 11-micromolar total AAT threshold or higher; the FDA viewed the biomarker dataset as approvable for accelerated approval.
BEAM-301 for G6PC R83C showed two patients at 40 mg fasting for 15 hours versus a prior maximum of two hours; dose escalation is proceeding to 60 mg.
One BEAM-301 participant responded less, with compound heterozygosity and BMI 53 cited as possible factors; lower-dose participants are expected eventually to receive the optimal biological dose, without a timeline.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update